Pharmaceutical company Boehringer-Ingelheim has notified us that the shortage of Metalyse (tenecteplase) is resolved. It is now available for use in all clinical settings and the conservation methods that have been in place since 2022 are lifted.
To support ongoing supply of Metalyse for all service providers, please order quantities based on your current needs and do not stockpile the product. Please consider using any existing stock of other thrombolytic medicines if you plan to transition back to Metalyse.
We thank the clinicians, health services and organisations involved for supporting the conservation strategies that played a key role in minimising the impact of this critical shortage in Australia.
For more information, go to our webpage about the Metalyse shortage and the Medicine shortage reports database.